Xeloda

capecitabine

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

Xeloda is a cancer medicine that is used to treat:

colon (large bowel) cancer. Xeloda is used on its own or with other cancer medicines in patients who have had surgery for stage III or Dukes’ stage C colon cancer;
metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body). Xeloda is used on its own or with other cancer medicines;
advanced gastric (stomach) cancer. Xeloda is used with other cancer medicines, including a platinum-containing cancer medicine such as cisplatin;
locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body). Xeloda is used with docetaxel (another cancer medicine) after treatment with anthracyclines (another type of cancer medicine) has failed. It can also be used on its own when treatment with both anthracyclines and taxanes (another type of cancer medicine) has failed or when further treatment with anthracyclines is not suitable for the patient.

Xeloda contains the active substance capecitabine.

: Xeloda should only be prescribed by a doctor who is experienced in the use of cancer medicines.

Before starting treatment, it is recommended that patients are tested to check that they have a working dihydropyrimidine dehydrogenase (DPD) enzyme.

Xeloda is available as tablets (150 and 500 mg). The dose depends on the patient’s height and weight and the type of cancer being treated. Xeloda tablets should be taken within 30 minutes after a meal. The tablets are given twice daily for 14 days followed by a 7-day gap before the next course.

Treatment is continued for 6 months after colon surgery. For other types of cancer, treatment is stopped if the disease gets worse or the side effects are unacceptable. Doses need to be adjusted for patients with liver or kidney disease and for patients who develop certain side effects. For patients with partial DPD deficiency, a lower starting dose may be considered.

For more information about using Xeloda, see the package leaflet or contact your doctor or pharmacist.

: The active substance in Xeloda, capecitabine, is a cytotoxic medicine (a medicine that kills rapidly dividing cells, such as cancer cells) that belongs to the group ‘anti-metabolites’. Capecitabine is converted to the medicine fluorouracil in the body, but more is converted in tumour cells than in normal tissues.

Fluorouracil is very similar to pyrimidine. Pyrimidine is part of the genetic material of cells (DNA and RNA). In the body, fluorouracil takes the place of pyrimidine and interferes with the enzymes involved in making new DNA. As a result, it prevents the growth of tumour cells and eventually kills them.

: Colon cancer

In colon cancer, Xeloda on its own has been shown to be as effective as the combination of fluorouracil and folinic acid (a medicine that enhances the effects of fluorouracil) in a main study involving 1,987 patients who had had surgery for their cancer. About two-thirds of the patients taking Xeloda or the combination remained disease-free throughout the 3.8 years of the study.

Another study involving 1,886 patients who had had surgery showed that Xeloda together with oxaliplatin (another cancer medicine) was more effective than the combination of fluorouracil and folinic acid: patients taking Xeloda and oxaliplatin had 20% lower risk of getting cancer again or death compared with patients taking fluorouracil and folinic acid.

Colorectal cancer

In metastatic colorectal cancer, Xeloda taken on its own was as effective as the combination of fluorouracil and folinic acid in 2 studies involving 1,207 patients. The disease responded in 19 to 25% of patients treated with Xeloda, compared with 12 to 15% with the comparator combination.

Xeloda has also been compared with the combination of fluorouracil and folinic acid, both used in combination with oxaliplatin, in 2 studies: the first involved 2,035 patients who had not been treated before, and the second involved 627 patients in whom previous treatment with irinotecan and a fluoropyrimidine (a group of cancer medicines that includes fluorouracil) had not worked. Results showed that when either Xeloda or fluorouracil and folinic acid were used with oxaliplatin, it took an average of 8 months for the disease to get worse in patients who had not been treated before, and 5 months in patients whose previous treatment had not worked.

Gastric cancer

In advanced gastric cancer, Xeloda with cisplatin was as effective as a combination of fluorouracil and cisplatin in slowing down the disease in a study involving 316 patients. It took 5.6 months for the disease to get worse in patients taking Xeloda and cisplatin, and 5.0 months in patients receiving fluorouracil and cisplatin. Also, the results of a published study involving 1,002 patients showed that patients taking combinations of medicines that included Xeloda survived for a similar period as those taking combinations that included fluorouracil.

Breast cancer

In locally advanced or metastatic breast cancer, Xeloda with docetaxel was more effective than docetaxel on its own in a study involving 511 women. Patients taking Xeloda with docetaxel had a longer time before the disease got worse compared with patients taking docetaxel on its own (186 days compared with 128 days). Two smaller studies (238 patients) showed that Xeloda was effective after treatment with taxanes and anthracyclines did not work.

The most common side effects with Xeloda are diarrhoea, nausea (feeling sick), vomiting, abdominal (belly) pain, stomatitis (sores in the mouth), palmar-plantar erythrodysaesthesia (hand-foot syndrome, a skin reaction with rash and pain on the hands and feet), tiredness, weakness, loss of appetite, problems due to formation of blood clots in the blood vessels, heart problems and kidney problems in patients who already have reduced kidney function. For the full list of side effects reported with Xeloda, see the package leaflet.

Xeloda must not be used in people who may be hypersensitive (allergic) to capecitabine, to any of the other ingredients, or to fluorouracil. Xeloda must also not be used in the following groups:

patients who have had severe and unexpected reactions to fluoropyrimidine therapy;
patients known to have no DPD enzyme activity;
pregnant or breastfeeding women;
patients with severe leucopenia, neutropenia, or thrombocytopenia (low levels of white cells or platelets in the blood);
patients with severe liver or kidney disease;
patients taking brivudine (an antiviral medicine for treating shingles or chickenpox) or who have taken it in the last 4 weeks.

: Xeloda has been shown to be effective in treating colon, colorectal, gastric and breast cancer. The safety profile of the medicine is considered acceptable. The European Medicines Agency therefore decided that Xeloda’s benefits are greater than its risks and it can be authorised for use in the EU.

: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xeloda have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xeloda are continuously monitored. Side effects reported with Xeloda are carefully evaluated and any necessary action taken to protect patients.

: Xeloda received a marketing authorisation valid throughout the EU on 2 February 2001.

List item

Xeloda : EPAR - Summary for the public (PDF/157.06 KB)

First published: 04/12/2008
Last updated: 27/07/2020
EMA/373967/2020
- Bulgarian
  (PDF/180.77 KB)
- Croatian
  (PDF/180.59 KB)
- Czech
  (PDF/183.67 KB)
- Danish
  (PDF/155.81 KB)
- Dutch
  (PDF/157.24 KB)
- Estonian
  (PDF/143.26 KB)
- Finnish
  (PDF/153.28 KB)
- French
  (PDF/157.08 KB)
- German
  (PDF/161.07 KB)
- Greek
  (PDF/186.66 KB)
- Hungarian
  (PDF/182.21 KB)
- Italian
  (PDF/154.98 KB)
- Latvian
  (PDF/193.75 KB)
- Lithuanian
  (PDF/179.22 KB)
- Maltese
  (PDF/180.97 KB)
- Polish
  (PDF/184.35 KB)
- Portuguese
  (PDF/155.85 KB)
- Romanian
  (PDF/177.41 KB)
- Slovak
  (PDF/182.05 KB)
- Slovenian
  (PDF/179.51 KB)
- Spanish
  (PDF/155.45 KB)
- Swedish
  (PDF/155.08 KB)

This EPAR was last updated on 26/10/2022

Authorisation details

Product details
Name	Xeloda
Agency product number	EMEA/H/C/000316
Active substance	capecitabine
International non-proprietary name (INN) or common name	capecitabine
Therapeutic area (MeSH)	Colonic Neoplasms Breast Neoplasms Colorectal Neoplasms Stomach Neoplasms
Anatomical therapeutic chemical (ATC) code	L01BC06

Publication details
Marketing-authorisation holder	CHEPLAPHARM Arzneimittel GmbH
Revision	30
Date of issue of marketing authorisation valid throughout the European Union	02/02/2001
Contact address	Ziegelhof 24 17489 Greifswald Germany

Product information

25/10/2022 Xeloda - EMEA/H/C/000316 - IAIN/0099/G

List item

Xeloda : EPAR - Product Information (PDF/518.17 KB)

First published: 05/12/2008
Last updated: 26/10/2022
- Bulgarian
  (PDF/1.02 MB)
- Croatian
  (PDF/992.92 KB)
- Czech
  (PDF/1.05 MB)
- Danish
  (PDF/550.27 KB)
- Dutch
  (PDF/552.11 KB)
- Estonian
  (PDF/547.07 KB)
- Finnish
  (PDF/534.69 KB)
- French
  (PDF/621.86 KB)
- German
  (PDF/404.78 KB)
- Greek
  (PDF/1.07 MB)
- Hungarian
  (PDF/832.99 KB)
- Icelandic
  (PDF/541.04 KB)
- Italian
  (PDF/549.22 KB)
- Latvian
  (PDF/1.08 MB)
- Lithuanian
  (PDF/1.07 MB)
- Maltese
  (PDF/1.03 MB)
- Norwegian
  (PDF/547.91 KB)
- Polish
  (PDF/1.01 MB)
- Portuguese
  (PDF/537.06 KB)
- Romanian
  (PDF/1.02 MB)
- Slovak
  (PDF/1.01 MB)
- Slovenian
  (PDF/961.49 KB)
- Spanish
  (PDF/577.75 KB)
- Swedish
  (PDF/524.74 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Xeloda : EPAR - All Authorised presentations (PDF/14.86 KB)

First published: 07/12/2005
Last updated: 07/12/2005
- Bulgarian
  (PDF/79.13 KB)
- Czech
  (PDF/42.34 KB)
- Danish
  (PDF/15.2 KB)
- Dutch
  (PDF/14.8 KB)
- Estonian
  (PDF/15.58 KB)
- Finnish
  (PDF/15.33 KB)
- French
  (PDF/15.34 KB)
- German
  (PDF/15.09 KB)
- Greek
  (PDF/75.69 KB)
- Hungarian
  (PDF/79.47 KB)
- Italian
  (PDF/14.86 KB)
- Latvian
  (PDF/80.45 KB)
- Lithuanian
  (PDF/79.17 KB)
- Maltese
  (PDF/77.68 KB)
- Polish
  (PDF/45.91 KB)
- Portuguese
  (PDF/15.53 KB)
- Romanian
  (PDF/76.34 KB)
- Slovak
  (PDF/44.07 KB)
- Slovenian
  (PDF/15.02 KB)
- Spanish
  (PDF/15.57 KB)
- Swedish
  (PDF/15.34 KB)

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.
Xeloda is indicated for the treatment of metastatic colorectal cancer.
Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.
Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Assessment history

Changes since initial authorisation of medicine

List item

Xeloda : EPAR - Procedural steps taken and scientific information after authorisation (PDF/275.78 KB)

First published: 05/12/2008
Last updated: 26/10/2022
List item

Xeloda-H-C-316-A31-1481 : EPAR - Scientific conclusions - Article 31 (PDF/153.51 KB)

First published: 30/07/2020
- Bulgarian
  (PDF/153.84 KB)
- Croatian
  (PDF/159.55 KB)
- Czech
  (PDF/160.26 KB)
- Danish
  (PDF/151.3 KB)
- Dutch
  (PDF/144.7 KB)
- Estonian
  (PDF/146.06 KB)
- Finnish
  (PDF/142.69 KB)
- French
  (PDF/155.05 KB)
- German
  (PDF/151.35 KB)
- Greek
  (PDF/155.31 KB)
- Hungarian
  (PDF/156.62 KB)
- Icelandic
  (PDF/152.16 KB)
- Italian
  (PDF/149.57 KB)
- Latvian
  (PDF/172.71 KB)
- Lithuanian
  (PDF/170.51 KB)
- Maltese
  (PDF/179.14 KB)
- Norwegian
  (PDF/141.47 KB)
- Polish
  (PDF/148.76 KB)
- Portuguese
  (PDF/153.64 KB)
- Romanian
  (PDF/158.9 KB)
- Slovak
  (PDF/167.72 KB)
- Slovenian
  (PDF/158.32 KB)
- Spanish
  (PDF/151.95 KB)
- Swedish
  (PDF/141.88 KB)
List item

Xeloda-H-C-316-A31-1481 : EPAR - Assessment Report - Article 31 (PDF/983.27 KB)

Adopted

First published: 30/07/2020
EMA/274404/2020
List item

Xeloda-H-C-316-PSUSA-00000531-201804 : EPAR - Scientific Conclusion (PDF/77.77 KB)

Adopted

First published: 28/08/2019
EMA/CHMP/455409/2019
List item

Xeloda-H-C-316-II-0058 : EPAR - Assessment Report - Variation (PDF/270.68 KB)

Adopted

First published: 20/03/2014
Last updated: 20/03/2014
EMA/CHMP/14148/2014
List item

Xeloda-H-C-316-A20-0048 : EPAR - Assessment Report - Article 20 (PDF/108.84 KB)

Adopted

First published: 21/11/2012
Last updated: 21/11/2012
EMA/568020/2012
List item

Xeloda-H-C-316-II-0028 : EPAR - Assessment Report - Variation (PDF/699.38 KB)

First published: 02/04/2008
Last updated: 02/04/2008
List item

Xeloda-H-C-316-II-0018 : EPAR - Scientific Discussion - Variation (PDF/432.18 KB)

Adopted

First published: 10/07/2007
Last updated: 10/07/2007
List item

Xeloda : EPAR - Steps taken after authorisation when a cutoff date has been used (PDF/83.94 KB)

First published: 07/12/2005
Last updated: 07/12/2005

Xeloda

Table of contents

Overview

Xeloda : EPAR - Summary for the public (PDF/157.06 KB)

Authorisation details

Product information

Xeloda : EPAR - Product Information (PDF/518.17 KB)

Xeloda : EPAR - All Authorised presentations (PDF/14.86 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Xeloda : EPAR - Procedural steps taken and scientific information after authorisation (PDF/275.78 KB)

Xeloda-H-C-316-A31-1481 : EPAR - Scientific conclusions - Article 31 (PDF/153.51 KB)

Xeloda-H-C-316-A31-1481 : EPAR - Assessment Report - Article 31 (PDF/983.27 KB)

Xeloda-H-C-316-PSUSA-00000531-201804 : EPAR - Scientific Conclusion (PDF/77.77 KB)

Xeloda-H-C-316-II-0058 : EPAR - Assessment Report - Variation (PDF/270.68 KB)

Xeloda-H-C-316-A20-0048 : EPAR - Assessment Report - Article 20 (PDF/108.84 KB)

Xeloda-H-C-316-II-0028 : EPAR - Assessment Report - Variation (PDF/699.38 KB)

Xeloda-H-C-316-II-0018 : EPAR - Scientific Discussion - Variation (PDF/432.18 KB)

Xeloda : EPAR - Steps taken after authorisation when a cutoff date has been used (PDF/83.94 KB)

Initial marketing-authorisation documents

Xeloda : EPAR - Procedural steps taken before authorisation (PDF/93.43 KB)

Xeloda : EPAR - Scientific Discussion (PDF/1.87 MB)

News

More information about Xeloda

Questions and answers on the review of centrally authorised medicines with ingredients manufactured at Roche Carolina Inc., Florence, United States (PDF/81.91 KB)

Direct healthcare professional communications (DHPC)

Related content

How useful was this page?